Tirzepatide: Dual-Agonist Research, Market Pricing, and Supply Chain Red Flags
Tirzepatide draws more monthly search interest than any other compound we track. It also has the widest gap between the quality of its clinical evidence and the quality of its grey-market supply.
10mg
Typical vial
$79
Lowest tracked
$128
Median price
143
Vendors listing
Dual agonism in plain terms
Tirzepatide activates both the GIP and GLP-1 receptors, rather than GLP-1 alone. In head-to-head trial programmes this produced larger effects on glycaemic and weight endpoints than single-receptor comparators.
Our index references around 410 studies, dominated by large randomised trials with predefined endpoints — the reason it carries a Strong evidence grade.
Where research-grade supply goes wrong
The synthesis is more complex than a single-agonist peptide, so shortcuts are more consequential. Truncated sequences and deletion impurities are the failure modes to look for on an HPLC trace.
A single peak at the expected retention time is not enough on its own; the impurity profile matters.
Price bands
10mg vials sit between roughly £62 and £101 in our tracked data. Tirzepatide is consistently the second most expensive compound in the index after retatrutide.
Because vial sizes vary widely here, price per milligram is the only comparison worth making.
Supplier scoring notes
Vendors that publish batch-matched certificates for every GLP-class product, rather than a single representative batch, sit at the top of this category in our rankings.
We downweight vendors whose certificates are hosted as unlinked images with no lab identification.
Frequently asked
Is tirzepatide stronger than semaglutide?
In published head-to-head trials it produced larger effects on the studied endpoints. That is a statement about trial results, not a recommendation.
Why is it more expensive?
A longer, more complex synthesis with lower yield, plus higher demand relative to available supply.
Search focus for this profile
tirzepatide — 823,000/mo searches, difficulty 91/100 — very hard. Source: Semrush (UK database).
Supporting terms covered: tirzepatide review, tirzepatide vs semaglutide, dual agonist peptide.
Everything below describes published research and market data. Nothing here is medical advice, and none of these compounds are sold or supplied by CheckALab.
More in Metabolic
Semaglutide
GLP-1 receptor agonist with a large human clinical trial record in metabolic research.
Retatrutide
Triple agonist with phase 2 metabolic results published and phase 3 ongoing.
Survodutide
GLP-1 and glucagon dual agonist with published phase 2 metabolic and liver outcomes.
5-Amino-1MQ
Small-molecule NNMT inhibitor studied in adipocyte and metabolic models.
Liraglutide
First-generation GLP-1 agonist with a large clinical trial literature behind it.
Lipo-C
Lipotropic compounded solution of methionine, inositol, choline and B vitamins.
AOD9604
Growth hormone fragment 176-191 studied for lipolytic activity, with human trial data.
Mazdutide
GLP-1 and glucagon dual agonist based on oxyntomodulin, with phase 3 data in China.
MOTS-c
Mitochondrial-derived peptide studied in exercise metabolism and insulin sensitivity models.